scholarly journals The Viral Polymerase Inhibitor 2'-C-Methylcytidine Inhibits Norwalk Virus Replication and Protects against Norovirus-Induced Diarrhea and Mortality in a Mouse Model

2013 ◽  
Vol 87 (21) ◽  
pp. 11798-11805 ◽  
Author(s):  
J. Rocha-Pereira ◽  
D. Jochmans ◽  
Y. Debing ◽  
E. Verbeken ◽  
M. S. J. Nascimento ◽  
...  
2016 ◽  
Vol 132 ◽  
pp. 46-49 ◽  
Author(s):  
Abimbola O. Kolawole ◽  
Joana Rocha-Pereira ◽  
Michael D. Elftman ◽  
Johan Neyts ◽  
Christiane E. Wobus

2020 ◽  
Author(s):  
Na Sun ◽  
Hua Zhang ◽  
Panpan Sun ◽  
Ajab Khan ◽  
Jianhua Guo ◽  
...  

Abstract BackgroundPRRSV and PCV2 co-infection is very common in swine industry which results in huge economic losses worldwide. Although vaccination is used to prevent viral diseases, immunosuppression induced by PRRSV and PCV2 leads to vaccine failure. Our previous results have demonstrated that Matrine possessed antiviral activities against PRRSV/PCV2 co-infection in vitro. To establish a PRRSV/PCV2 co-infected KM mouse model and evaluate the antiviral activities of Matrine against PRRSV/PCV2 co-infection. A total of 144 KM mice were randomly divided into six groups with 24 mice in each group, named as: normal control, PRRSV/PCV2 co-infected group (PRRSV/PCV2 group), Ribavirin treatment positive control (Ribavirin control) and Matrine treatment groups (Matrine 40 mg/kg, Matrine 20 mg/kg and Matrine 10 mg/kg). Except normal control group, all mice in other five groups were inoculated with PRRSV, followed by PCV2 at 2 h later. At 7 days post-infection (dpi), mice in the treatment groups were intraperitoneally administered with various doses of Matrine and Ribavirin, twice a day for 5 consecutive days. ResultsPRRSV N and PCV2 CAP genes were detected by PCR in multiple tissues including heart, liver, spleen, lungs, kidneys, thymus and inguinal lymph nodes. The viral load of PCV2 was the highest in liver followed by thymus and spleen. Although PRRSV were detected in most of the tissues, but the replication of PRRSV was not significantly increased, as shown by qPCR analysis. Comparing with PCV2 infection alone, PRRSV infection significantly elevated PCV2 replication and also exacerbated PCV2 induced interstitial pneumonia. qPCR analysis demonstrated that 40 mg/ml Matrine significantly attenuated PCV2 replication in liver and alleviated virus induced interstitial pneumonia, suggesting that Matrine could directly inhibit virus replication. In addition, Matrine treatment enhanced peritoneal macrophages phagocytosis at 13 and 16 dpi, and 40 mg/kg of Matrine increased the proliferation activity of lymphocytes. Body weight gain was continuously promoted by administrating Matrine at 10 mg/kg.ConclusionMatrine possessed antiviral activities via inhibiting virus replication and regulating immune functions in mice co-infected by PRRSV/PCV2. These data provide new insight into controlling PRRSV and PCV2 infection and support further the research for developing Matrine as a new possible veterinary medicine.


2020 ◽  
Vol 165 (3) ◽  
pp. 671-681 ◽  
Author(s):  
Leonardo C. de Oliveira ◽  
Aryádina M. Ribeiro ◽  
Jonas D. Albarnaz ◽  
Alice A. Torres ◽  
Luís F. Z. Guimarães ◽  
...  

2012 ◽  
Vol 32 (8) ◽  
pp. 1306-1314 ◽  
Author(s):  
Wenwei Yin ◽  
Long Xu ◽  
Rui Sun ◽  
Haiming Wei ◽  
Zhigang Tian

2016 ◽  
Author(s):  
Joanna Zmurko ◽  
Rafael E Marques ◽  
Dominique Schols ◽  
Erik Verbeken ◽  
Suzanne J.F. Kaptein ◽  
...  

Zika virus (ZIKV) is an emerging flavivirus typically causing a dengue-like febrile illness, but neurological complications, such as microcephaly in newborns, have potentially been linked to this viral infection. We established a panel of in vitro assays to allow the identification of ZIKV inhibitors and demonstrate that the viral polymerase inhibitor 7-deaza-2'-C-methyladenosine (7DMA) efficiently inhibits replication. Infection of AG129 (IFN-α/β and IFN-γ receptor knock-21 out) mice with ZIKV resulted in acute neutrophilic encephalitis with viral antigens accumulating in neurons of the brain and spinal cord. Additionally, high levels of viral RNA were detected in the spleen, liver and kidney, and levels of IFN-γ and IL-18 were systematically increased in serum of ZIKV-infected mice. Interestingly, the virus was also detected in testicles of infected mice. In line with its in vitro anti-ZIKV activity, 7DMA reduced viremia and delayed virus-induced morbidity and mortality in infected mice, which also validates this small animal model to assess the in vivo efficacy of novel ZIKV inhibitors. Since AG129 mice can generate an antibody response, and have been used in dengue vaccine studies, the model can also be used to assess the efficacy of ZIKV vaccines.


2021 ◽  
Author(s):  
Maren de Vries ◽  
Adil S. Mohamed ◽  
Rachel A. Prescott ◽  
Ana M. Valero-Jimenez ◽  
Ludovic Desvignes ◽  
...  

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of Coronavirus Disease 2019 (COVID-19). There is a dire need for novel effective antivirals to treat COVID-19, as the only approved direct-acting antiviral to date is remdesivir, targeting the viral polymerase complex. A potential alternate target in the viral life cycle is the main SARS-CoV-2 protease 3CLpro (Mpro). The drug candidate PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials. Here, we perform a comparative analysis of PF-00835231, the pre-clinical 3CLpro inhibitor GC-376, and the polymerase inhibitor remdesivir, in alveolar basal epithelial cells modified to express ACE2 (A549+ACE2 cells). We find PF-00835231 with at least similar or higher potency than remdesivir or GC-376. A time-of-drug-addition approach delineates the timing of early SARS-CoV-2 life cycle steps in A549+ACE2 cells and validates PF-00835231’s early time of action. In a model of the human polarized airway epithelium, both PF-00835231 and remdesivir potently inhibit SARS-CoV-2 at low micromolar concentrations. Finally, we show that the efflux transporter P-glycoprotein, which was previously suggested to diminish PF-00835231’s efficacy based on experiments in monkey kidney Vero E6 cells, does not negatively impact PF-00835231 efficacy in either A549+ACE2 cells or human polarized airway epithelial cultures. Thus, our study provides in vitro evidence for the potential of PF-00835231 as an effective SARS-CoV-2 antiviral and addresses concerns that emerged based on prior studies in non-human in vitro models. Importance: The arsenal of SARS-CoV-2 specific antiviral drugs is extremely limited. Only one direct-acting antiviral drug is currently approved, the viral polymerase inhibitor remdesivir, and it has limited efficacy. Thus, there is a substantial need to develop additional antiviral compounds with minimal side effects and alternate viral targets. One such alternate target is its main protease, 3CLpro (Mpro), an essential component of the SARS-CoV-2 life cycle processing the viral polyprotein into the components of the viral polymerase complex. In this study, we characterize a novel antiviral drug, PF-00835231, which is the active component of the first-in-class 3CLpro-targeting regimen in clinical trials. Using 3D in vitro models of the human airway epithelium, we demonstrate the antiviral potential of PF-00835231 for inhibition of SARS-CoV-2.


2008 ◽  
Vol 33 (8) ◽  
pp. 655 ◽  
Author(s):  
R.G. Painter ◽  
C.L. Trost ◽  
M.B. Lampert ◽  
R.M. Almond ◽  
M. Buller ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document